Quetiapine fumarate extended-release for the treatment of major depression with comorbid fibromyalgia syndrome: A double-blind, randomized, placebo-controlled study

Arthritis and Rheumatology

Volumn 66, Issue 2, 2014, Pages 451-461

  McIntyre, Alexander ^a   Paisley, David ^a   Kouassi, Edouard ^b   Gendron, Alain ^b,c  

^a Penticton Regional Hospital   (Canada)

^b CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE MONTRÉAL   (Canada)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CHOLESTEROL; GABAPENTIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPNOTIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; PREGABALIN; QUETIAPINE; TEMAZEPAM; THYROTROPIN; TOPIRAMATE; TRIACYLGLYCEROL; ZOPICLONE;

ADULT; ANXIETY; ARTICLE; BLURRED VISION; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; EVENING DOSAGE; EXTENDED DRUG RELEASE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; FIBROMYALGIA; GASTROESOPHAGEAL REFLUX; HAMILTON SCALE; HEART PALPITATION; HEARTBURN; HUMAN; HYPOTENSION; INCREASED APPETITE; INFLUENZA; INSOMNIA; IRRITABILITY; LARYNGITIS; LETHARGY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; MUSCLE TWITCH; MYALGIA; NAUSEA AND VOMITING; NIGHTMARE; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESS LEGS SYNDROME; RESTLESSNESS; SEDATION; SIDE EFFECT; SLEEP WALKING; SOMNOLENCE; STREPTOCOCCAL PHARYNGITIS; THORAX PAIN; THYROTROPIN BLOOD LEVEL; TINNITUS; TONGUE SWELLING; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SAFETY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84896262426     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38228     Document Type: Article

References (47)

1. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67: 536-41.
2. Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum 2008;59: 952-60.
3. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33: 160-72.
4. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38: 19-28.
5. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010;39: 448-53.
6. White KP, Speechley M, Harth M, Ostbye T. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999;26: 1570-6.
7. Fuller-Thomson E, Nimigon-Young J, Brennenstuhl S. Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey. Rheumatol Int 2012;32: 853-62.
8. Arnold LM, Hudson JI, Keck PE, Auchenback MB, Javaras KN, Hess EV. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006;67: 1219-25.
9. Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med 2004;66: 837-44.
10. Maletic V, Raison CL. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci 2009;14: 5291-338.
11. Nagakura Y, Oe T, Aoki T, Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia. Pain 2009;146: 26-33.
12. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35: 550-6.
13. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37: 1593-601.
14. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999;26: 1564-9.
15. Wood PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008;8: 781-97.
16. Potvin S, Grignon S, Marchand S. Human evidence of a supraspinal modulating role of dopamine on pain perception. Synapse 2009;63: 390-402.
17. Offenbaecher M, Bondy B, de Jonge S, Glatzeder K, Kruger M, Schoeps P, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999;42: 2482-8.
18. Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012;26: 297-307.
19. Uceyler N, Hauser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008;59: 1279-98.
20. Arnold LM, Clauw DJ, Wohlreich MM, Wang F, Ahl J, Gaynor PJ, et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. Prim Care Companion J Clin Psychiatry 2009;11: 237-44.
21. Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia. Pain Pract 2011;11: 120-31.
22. Holman AJ, Myers RR. A randomized, double-blind, placebocontrolled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52: 2495-505.
23. Holman AJ. Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14-week double-blind, pilot, randomized controlled trial with 14-week blinded extension [abstract]. Arthritis Rheum 2004;50:S698.
24. Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002;956: 349-57.
25. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008;33: 2303-12.
26. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010;121: 106-15.
27. Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol 2012;27: 27-39.
28. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 2010;27: 964-76.
29. Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, Earley W, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry 2013;21: 769-84.
30. Calandre EP, Rico-Villademoros F. The role of antipsychotics in the management of fibromyalgia. CNS Drugs 2012;26: 135-53.
31. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18: 728-34.
32. Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31: 71-7.
33. Potvin S, Morin M, Cloutier C, Gendron A, Bissonnette A, Marchand S. Add-on treatment of quetiapine for fibromyalgia: a pilot randomized, double-blind, placebo-controlled 12-week trial. J Clin Psychopharmacol 2012;32: 684-7.
34. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Janavs J, Weiller E, Bonara LI, et al. Reliability and validity of the MINI International Neuropsychiatric Interview (M.I.N.I.): according to the SCID-P. Eur Psychiatry 1997;12: 232-41.
35. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23: 56-62.
36. Guy W. US Department of Health, Education, and Welfare. Assessment manual for psychopharmacology-revised. DHEW Pub. No. [ADM] 76-338. Rockville (MD): US Department of Health, Education, and Welfare; 1976. p. 218-22.
37. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33: 160-72.
38. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23: 129-38.
39. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32: 50-5.
40. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11: 89-95.
41. Endicott J, Nee J, Harrison W, Blumenthal, R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29: 321-6.
42. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002;64: 258-66.
43. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33: 766-71.
44. Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med 2004;19: 813-8.
45. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50: 2974-84.
46. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the Fibromyalgia Impact Questionnaire. J Rheumatol 2009;36: 1304-11.
47. Cousin C, Yang H, Yeung A, Fava M. Rating scales for depression. In: Baer L, Blais MA, editors. Handbook of clinical rating scales and assessment in psychiatry and mental health. New York: Humana Press; 2010.